Results of ESBA 1008, a Single-Chain Antibody Fragment, for the Treatment of Neovascular AMD

Pravin Dugel, MD

Show Description +

Pravin Dugel, MD, from Retinal Consultants of Arizona, shares study results on ESBA 1008, a single-chain antibody fragment with potential applications in targeting VEGF.

Posted: 8/08/2014

Up Next

Name: Results of ESBA 1008, a Single-Chain Antibody Fragment, for the Treatment of Neovascular AMD
Uploaded: 2014-08-08T16:13:00+00:00
Description: Pravin Dugel, MD, from Retinal Consultants of Arizona, shares study results on ESBA 1008, a single-chain antibody fragment with potential applications in targeting VEGF.

$Dexamethasone Intravitreal Implant in Diabetic Macular Edema Patients Refractory to Conventional Therapy$

Dexamethasone Intravitreal Implant in Diabetic Macular Edema Patients Refractory to Conventional Therapy

David G. Dodwell, MD

Preview - What to Watch for in San Diego!

Rishi Singh, MD

Evaluation of Intraocular Inflammation and Pain Post Intravitreal Injection of Ranibizumab or Aflibercept: The PLANET Study

Arshad M. Khanani, MD, Nikolas J.S. London, MD

Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration With Pigment Epithelial Detachment

Nikolas J.S. London, MD, Rahul Khurana, MD

Microincisional Vitrectomy (MIVS) in the Primary Management of Uveal Malignant Melanoma: Application of Direct Tumor Ablation and Molecular Genomics

Tim Murray, MD

Next Generation Intrasurgical Imaging with a Swept-Source Microscope-Integrated Optical Coherence Tomography Device

Paul Hahn, MD

Optical Coherence Tomography Measurement of Retinal Pigment Epithelium Drusen Complex Predicts 2-Year Progression of Age-Related Macular Degeneration

Nikolas J.S. London, MD, Sumit Sharma, MD

Intraocular Pharmacokinetic Profile of Aflibercept in Patients Treated With Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration

Clement K. Chan, MD, FACS

Changes in Hydroxychloroquine Retinopathy Following Drug Cessation: With Expanded SD-OCT Findings to Assist in the Early Detection of Retinopathy

David Lally, MD, Nikolas J.S. London, MD

Long-Term Treatment Outcomes for Neovascular Age-Related Macular Degeneration Using a Treat-and-Extend Regimen

Carl Regillo, MD, Nikolas J.S. London, MD

Real-World Vision Outcomes in DME Treated with Anti-VEGF Injections - An Analysis of EMR Data from a Large US Health System

Nancy Holekamp MD

Back to All Videos

Results of ESBA 1008, a Single-Chain Antibody Fragment, for the Treatment of Neovascular AMD

Pravin Dugel, MD

Pravin Dugel, MD, from Retinal Consultants of Arizona, shares study results on ESBA 1008, a single-chain antibody fragment with potential applications in targeting VEGF.

Posted: 8/08/2014

Please log in to leave a comment.

Meeting Coverage:

American Society of Retina Specialists Annual Meeting

Results of ESBA 1008, a Single-Chain Antibody Fragment, for the Treatment of Neovascular AMD

Up Next

Results of ESBA 1008, a Single-Chain Antibody Fragment, for the Treatment of Neovascular AMD

More From ASRS: 2014 Coverage